Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.65 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.65 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.65 |
| ▸ | DPP4 | P27487 | 3/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025186 | 0.81 | HDAC8 (1.00) | HDAC8DPP8DPP7DPP9DPP4 | |
| SCHEMBL8242087 | 0.81 | HDAC8 (1.00) | HDAC8DPP8DPP7DPP9DPP4 | |
| SCHEMBL4792049 | 0.81 | HDAC8 (0.74) | HDAC8DPP8DPP7DPP9DPP4 | |
| SCHEMBL4792054 | 0.81 | HDAC8 (0.74) | HDAC8DPP8DPP7DPP9DPP4 | |
| SCHEMBL4792058 | 0.81 | HDAC8 (0.74) | HDAC8DPP8DPP7DPP9DPP4 | |
| SCHEMBL4775624 | 0.80 | DPP8 (0.67) | HDAC8DPP8DPP7DPP9DPP4 | |
| SCHEMBL4775626 | 0.80 | DPP8 (0.67) | HDAC8DPP8DPP7DPP9DPP4 | |
| Hydrochloric Acid SCHEMBL6165480 | 0.80 | HDAC8 (1.00) | HDAC8DPP8DPP7DPP9DPP4 | |
| SCHEMBL21746926 | 0.79 | DPP7 (1.00) | HDAC8DPP8DPP7DPP9DPP4 | |
| SCHEMBL31653974 | 0.79 | DPP7 (1.00) | HDAC8DPP8DPP7DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018216823-A1 | ALPHA-AMINO AMIDE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2018-11-29 | — | — | WO | disclosed |